Kong, Xiangfeng
Zhang, Hainan
Li, Guoling
Wang, Zikang
Kong, Xuqiang
Wang, Lecong
Xue, Mingxing
Zhang, Weihong
Wang, Yao
Lin, Jiajia
Zhou, Jingxing
Shen, Xiaowen
Wei, Yinghui
Zhong, Na
Bai, Weiya
Yuan, Yuan
Shi, Linyu
Zhou, Yingsi
Yang, Hui http://orcid.org/0000-0002-8023-0230
Funding for this research was provided by:
This work was supported by HUIEDIT Therapeutics Inc. and HUIDAGENE Therapeutics Co., Ltd.
Article History
Received: 6 January 2023
Accepted: 31 March 2023
First Online: 11 April 2023
Competing interests
: H.Y. and L.S. are cofounders of HuidaGene Therapeutics Co., Ltd. (“HuidaGene”). H.Y. and Y.Z. are cofounders of HuiEdit Therapeutics Co., Ltd. (“HuiEdit”). Provisional patent applications PCT/CN2022/089053 and PCT/CN2022/142467 have been filed with inventors X.K., X.Q.K., and L.W. and owned by the patent applicant HuidaGene, claiming especially the CRISPR-Cas12 systems herein. The remaining authors declare no competing interests.